Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

Katerina Chatzidionysiou; Elisabeth Lie; Evgeny Nasonov; Galina Lukina; Merete Lund Hetland; Ulrik Tarp; Cem Gabay; Piet L C M van Riel; Dan C Nordström; Juan Gomez-Reino; Karel Pavelka; Matija Tomsic; Tore K Kvien; Ronald F van Vollenhoven

doi:10.1136/ard.2010.148759

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

Katerina Chatzidionysiou, Elisabeth Lie, Evgeny Nasonov, Galina Lukina, Merete Lund Hetland, Ulrik Tarp, Cem Gabay, Piet L C M van Riel, Dan C Nordström, Juan Gomez-Reino, Karel Pavelka, Matija Tomsic, Tore K Kvien, Ronald F van Vollenhoven

Institut for Klinisk Medicin

164 Citationer (Scopus)

Abstract

Objective: To assess the 6-month effectiveness of the first rituximab (RTX) course in rheumatoid arthritis (RA) and to identify possible predictors of response. Method: 10 European registries submitted anonymised datasets (baseline, 3-and 6-month follow-up) from patients with RA who had started RTX, and datasets were pooled and analysed. Heterogeneity between countries was analysed by analysis of variance. Predictors of response were identified by logistic regression. Results: 2019 patients were included (mean age/disease duration 53.8/12.1 years, 80.3% female, 85.6% rheumatoid factor (RF) positive and 76.8% (456/594 patients) anticyclic citrullinated peptide antibodies (anti-CCP) positive). For these patients an average of 2.7 disease-modifying antirheumatic drugs (DMARDs) (range 0-10) had failed, and RTX was given as the first biological agent in 36.6% of patients. There was significant heterogeneity between countries for several baseline characteristics, including the number of previous biological agents. Disease Activity Score based on 28 joint counts (DAS28) decreased from 5.8±1.4 at baseline to 4.2±1.4 at 6 months (p<0.0001) and 22.2%/42.5% achieved European League Against Rheumatism (EULAR) good/moderate response. Larger 6-month improvement in DAS28 was observed in RF-positive and anti-CCP-positive versus seronegative patients. The following predictors of EULAR good response at 6 months were identified in a multivariate analysis:anti- CCP positivity (OR=2.86, p=0.003), number of previous DMARDs (OR=0.84, p=0.06), ≤1 previous biological agents (OR=1.89, p=0.04), baseline DAS28 level (OR=0.74, p=0.003). Conclusion: In this large observational cohort of patients with RA treated with RTX, seropositive patients achieved significantly greater reductions in DAS28 at 6 months than seronegative patients. Effectiveness was best when RTX was used as the first biological agent or after failure of no more than one anti-tumour necrosis factor agent.

Originalsprog	Engelsk
Tidsskrift	Annals of the Rheumatic Diseases
Vol/bind	70
Udgave nummer	9
Sider (fra-til)	1575-1580
Antal sider	6
ISSN	0003-4967
DOI	https://doi.org/10.1136/ard.2010.148759
Status	Udgivet - sep. 2011

Adgang til dokumentet

10.1136/ard.2010.148759

Fingeraftryk

Dyk ned i forskningsemnerne om 'Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Chatzidionysiou, K., Lie, E., Nasonov, E., Lukina, G., Hetland, M. L., Tarp, U., Gabay, C., van Riel, P. L. C. M., Nordström, D. C., Gomez-Reino, J., Pavelka, K., Tomsic, M., Kvien, T. K., & van Vollenhoven, R. F. (2011). Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Annals of the Rheumatic Diseases, 70(9), 1575-1580. https://doi.org/10.1136/ard.2010.148759

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. / Chatzidionysiou, Katerina; Lie, Elisabeth; Nasonov, Evgeny et al.

I: Annals of the Rheumatic Diseases, Bind 70, Nr. 9, 09.2011, s. 1575-1580.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Chatzidionysiou, K, Lie, E, Nasonov, E, Lukina, G, Hetland, ML, Tarp, U, Gabay, C, van Riel, PLCM, Nordström, DC, Gomez-Reino, J, Pavelka, K, Tomsic, M, Kvien, TK & van Vollenhoven, RF 2011, 'Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries', Annals of the Rheumatic Diseases, bind 70, nr. 9, s. 1575-1580. https://doi.org/10.1136/ard.2010.148759

Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Annals of the Rheumatic Diseases. 2011 sep.;70(9):1575-1580. doi: 10.1136/ard.2010.148759

@article{b1fba4ca997d41128c5d8beca77f2e8c,

title = "Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries",

abstract = "Objective: To assess the 6-month effectiveness of the first rituximab (RTX) course in rheumatoid arthritis (RA) and to identify possible predictors of response. Method: 10 European registries submitted anonymised datasets (baseline, 3-and 6-month follow-up) from patients with RA who had started RTX, and datasets were pooled and analysed. Heterogeneity between countries was analysed by analysis of variance. Predictors of response were identified by logistic regression. Results: 2019 patients were included (mean age/disease duration 53.8/12.1 years, 80.3% female, 85.6% rheumatoid factor (RF) positive and 76.8% (456/594 patients) anticyclic citrullinated peptide antibodies (anti-CCP) positive). For these patients an average of 2.7 disease-modifying antirheumatic drugs (DMARDs) (range 0-10) had failed, and RTX was given as the first biological agent in 36.6% of patients. There was significant heterogeneity between countries for several baseline characteristics, including the number of previous biological agents. Disease Activity Score based on 28 joint counts (DAS28) decreased from 5.8±1.4 at baseline to 4.2±1.4 at 6 months (p<0.0001) and 22.2%/42.5% achieved European League Against Rheumatism (EULAR) good/moderate response. Larger 6-month improvement in DAS28 was observed in RF-positive and anti-CCP-positive versus seronegative patients. The following predictors of EULAR good response at 6 months were identified in a multivariate analysis:anti- CCP positivity (OR=2.86, p=0.003), number of previous DMARDs (OR=0.84, p=0.06), ≤1 previous biological agents (OR=1.89, p=0.04), baseline DAS28 level (OR=0.74, p=0.003). Conclusion: In this large observational cohort of patients with RA treated with RTX, seropositive patients achieved significantly greater reductions in DAS28 at 6 months than seronegative patients. Effectiveness was best when RTX was used as the first biological agent or after failure of no more than one anti-tumour necrosis factor agent.",

author = "Katerina Chatzidionysiou and Elisabeth Lie and Evgeny Nasonov and Galina Lukina and Hetland, {Merete Lund} and Ulrik Tarp and Cem Gabay and {van Riel}, {Piet L C M} and Nordstr{\"o}m, {Dan C} and Juan Gomez-Reino and Karel Pavelka and Matija Tomsic and Kvien, {Tore K} and {van Vollenhoven}, {Ronald F}",

year = "2011",

month = sep,

doi = "10.1136/ard.2010.148759",

language = "English",

volume = "70",

pages = "1575--1580",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "B M J Group",

number = "9",

}

TY - JOUR

T1 - Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries

AU - Chatzidionysiou, Katerina

AU - Lie, Elisabeth

AU - Nasonov, Evgeny

AU - Lukina, Galina

AU - Hetland, Merete Lund

AU - Tarp, Ulrik

AU - Gabay, Cem

AU - van Riel, Piet L C M

AU - Nordström, Dan C

AU - Gomez-Reino, Juan

AU - Pavelka, Karel

AU - Tomsic, Matija

AU - Kvien, Tore K

AU - van Vollenhoven, Ronald F

PY - 2011/9

Y1 - 2011/9

N2 - Objective: To assess the 6-month effectiveness of the first rituximab (RTX) course in rheumatoid arthritis (RA) and to identify possible predictors of response. Method: 10 European registries submitted anonymised datasets (baseline, 3-and 6-month follow-up) from patients with RA who had started RTX, and datasets were pooled and analysed. Heterogeneity between countries was analysed by analysis of variance. Predictors of response were identified by logistic regression. Results: 2019 patients were included (mean age/disease duration 53.8/12.1 years, 80.3% female, 85.6% rheumatoid factor (RF) positive and 76.8% (456/594 patients) anticyclic citrullinated peptide antibodies (anti-CCP) positive). For these patients an average of 2.7 disease-modifying antirheumatic drugs (DMARDs) (range 0-10) had failed, and RTX was given as the first biological agent in 36.6% of patients. There was significant heterogeneity between countries for several baseline characteristics, including the number of previous biological agents. Disease Activity Score based on 28 joint counts (DAS28) decreased from 5.8±1.4 at baseline to 4.2±1.4 at 6 months (p<0.0001) and 22.2%/42.5% achieved European League Against Rheumatism (EULAR) good/moderate response. Larger 6-month improvement in DAS28 was observed in RF-positive and anti-CCP-positive versus seronegative patients. The following predictors of EULAR good response at 6 months were identified in a multivariate analysis:anti- CCP positivity (OR=2.86, p=0.003), number of previous DMARDs (OR=0.84, p=0.06), ≤1 previous biological agents (OR=1.89, p=0.04), baseline DAS28 level (OR=0.74, p=0.003). Conclusion: In this large observational cohort of patients with RA treated with RTX, seropositive patients achieved significantly greater reductions in DAS28 at 6 months than seronegative patients. Effectiveness was best when RTX was used as the first biological agent or after failure of no more than one anti-tumour necrosis factor agent.

AB - Objective: To assess the 6-month effectiveness of the first rituximab (RTX) course in rheumatoid arthritis (RA) and to identify possible predictors of response. Method: 10 European registries submitted anonymised datasets (baseline, 3-and 6-month follow-up) from patients with RA who had started RTX, and datasets were pooled and analysed. Heterogeneity between countries was analysed by analysis of variance. Predictors of response were identified by logistic regression. Results: 2019 patients were included (mean age/disease duration 53.8/12.1 years, 80.3% female, 85.6% rheumatoid factor (RF) positive and 76.8% (456/594 patients) anticyclic citrullinated peptide antibodies (anti-CCP) positive). For these patients an average of 2.7 disease-modifying antirheumatic drugs (DMARDs) (range 0-10) had failed, and RTX was given as the first biological agent in 36.6% of patients. There was significant heterogeneity between countries for several baseline characteristics, including the number of previous biological agents. Disease Activity Score based on 28 joint counts (DAS28) decreased from 5.8±1.4 at baseline to 4.2±1.4 at 6 months (p<0.0001) and 22.2%/42.5% achieved European League Against Rheumatism (EULAR) good/moderate response. Larger 6-month improvement in DAS28 was observed in RF-positive and anti-CCP-positive versus seronegative patients. The following predictors of EULAR good response at 6 months were identified in a multivariate analysis:anti- CCP positivity (OR=2.86, p=0.003), number of previous DMARDs (OR=0.84, p=0.06), ≤1 previous biological agents (OR=1.89, p=0.04), baseline DAS28 level (OR=0.74, p=0.003). Conclusion: In this large observational cohort of patients with RA treated with RTX, seropositive patients achieved significantly greater reductions in DAS28 at 6 months than seronegative patients. Effectiveness was best when RTX was used as the first biological agent or after failure of no more than one anti-tumour necrosis factor agent.

U2 - 10.1136/ard.2010.148759

DO - 10.1136/ard.2010.148759

M3 - Journal article

SN - 0003-4967

VL - 70

SP - 1575

EP - 1580

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 9

ER -